Yumi Mitsuya, MD

Assistant Professor

Assistant Professor, Pediatric Rehabilitation Medicine

Physical Medicine and Rehabilitation

UCSF Benioff Children's Hospital Oakland - Pediatric Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation

744 52nd Street
Oakland CA 94609

510-428-3655

Publications

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW. Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother. 2013 Sep; 57(9):4290-4299. PMID: 23796938

Varghese V, Mitsuya Y, Shahriar R, Bachmann MH, Fessel WJ, Kagan RM, Shafer RW. Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility. Antimicrob Agents Chemother. 2009 May; 53(5):2196-8. PMID: 19223644

Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW. Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol. 2008 Nov; 82(21):10747-55. PMID: 18715933

Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, Gharizadeh B, Ronaghi M, Shafer RW, Beerenwinkel N. Viral population estimation using pyrosequencing. PLoS Comput Biol. 2008 May 09; 4(4):e1000074. PMID: 18437230

Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis. 2007 Oct 15; 196(8):1177-9. PMID: 17955436

Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007 Aug; 17(8):1195-201. PMID: 17600086

Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1300-5. PMID: 17209774

Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H, Mitsuya H. A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol. 2003 Feb; 120(3):396-404. PMID: 12580953

Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F, Mitsuya H. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol. 2003 Jan; 120(1):53-5. PMID: 12492576

Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Slome S, Flamm J, Horberg M, Hurley L, Klein D, Shafer RW. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. 2006 Sep; 43(1):56-9. PMID: 16885777

Education

	M.D.	Albany Medical College
	Residency, Physical Medicine and Rehabilitation	Stanford University
	Residency, Pediatrics	UCSF Benioff Children's Hospital Oakland

About Yumi Mitsuya, MD

Dr. Yumi Mitsuya is a pediatric physiatrist, who specializes in working with pediatric patients with spina bifida, neurotrauma, spasticity management, intrathecal baclofen pump management, spinal cord injury, cerebral palsy, brain injury, and neuromuscular disorders.

Faculty

Yumi Mitsuya, MD

Yumi Mitsuya, MD

UCSF Benioff Children's Hospital Oakland - Pediatric Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation 744 52nd Street Oakland CA 94609 510-428-3655

Publications

Education

About Yumi Mitsuya, MD

Related News

UCSF Benioff Children's Hospital Oakland - Pediatric Physical Medicine and Rehabilitation - Physical Medicine and Rehabilitation

744 52nd Street
Oakland CA 94609

510-428-3655